Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023

Interview with Ajai Chari, MD, from the University of California, San Fransisco at ASH 2023. Filmed December 10, 2023.

ASH ABSTRACT: Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
https://ash.confex.com/ash/2023/webpr...


The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at https://www.healthtree.org/myeloma/co...

Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/...

HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/

Follow HealthTree:
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instagram.com/healthtreeformultiplemyeloma